Who actually benefits from a PCSK9 inhibitor, and when should one be considered?

The clearest candidates are people whose cardiovascular risk and remaining LDL burden justify substantial additional lowering. This often includes established atherosclerotic disease or familial hypercholesterolemia, particularly when an appropriate statin regimen and other therapies have not achieved the needed reduction or cannot be tolerated. Treatment choice depends on the whole risk picture, including diabetes, kidney disease, family history and prior events. A single mildly elevated LDL result in an otherwise low-risk young adult is not equivalent to those situations.[1]

FOURIER established event reduction in patients with atherosclerotic cardiovascular disease. VESALIUS-CV extended the evidence to selected patients with atherosclerosis or high-risk diabetes who had not had a previous myocardial infarction or stroke. This is still a higher-risk population, not a trial of routine use in healthy lifters. The useful discussion is how much absolute benefit is expected over time, what alternatives can achieve the goal, and whether the practical burden is justified. The same relative reduction prevents more events when baseline risk is higher.[2][3]